Shanghai Allist Pharmaceuticals

Update in progress

688578.SS (Shanghai)

Shanghai Allist Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company focused on researching and developing tumor-targeted therapies. Its lead product, vometinib mesylate tablets, is being developed for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer, as well as adults with locally advanced or metastatic NSCLC. The company was founded in 2004 and is headquartered in Shanghai.